Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Monitoring Intravitreal Injection Patients
When a patient reports receiving intravitreal injections, it is important to find out how many injections the patient has had and what type because studies show a change in corneal nerve length and density after the third intravitreal injection.
Neurotrophic Keratitis (NK) induced by intravitreal injections
Key Mechanisms
Corneal nerve damage and reduced nerve density after multiple intravitreal injections, especially anti-VEGF agents which impair corneal nerve regeneration
Target Population
Patients receiving intravitreal injections for age-related macular degeneration and diabetic macular edema
Care Setting
Ophthalmology and optometry clinics managing patients undergoing intravitreal injections
Key Highlights
Corneal nerve length and density decrease notably after the third intravitreal injection.
Anti-VEGF injections can cause more corneal damage due to VEGF's role in nerve regeneration.
Early detection of NK via corneal sensitivity testing and fluorescein staining is critical to prevent progression.
Guideline-Based Recommendations
Diagnosis
Obtain detailed history of number and type of intravitreal injections.
Assess risk factors including diabetes, stroke, autoimmune disease, dry eye disease, and prior ocular surgeries.
Use the Ocular Surface Disease Index survey to evaluate vision-related symptoms.
Perform corneal sensitivity testing using Cochet-Bonnet or Brill esthesiometers, cotton wisp, or unwaxed dental floss without prior eye drop instillation.
Evaluate corneal fluorescein staining patterns focusing on central cornea and punctate epithelial defects.
Management
Educate patients on the importance of regular follow-up to monitor for NK progression.
Early intervention upon detection to prevent progression to stage 3 NK and vision loss.
Monitoring & Follow-up
Regular screening of intravitreal injection patients for signs of NK using sensitivity testing and slit lamp examination.
Monitor for conjunctival hyperemia, epithelial irregularity, stromal haze, punctate keratopathy, superficial vascularization, and stromal scarring.
Risks
Progression to severe NK (stage 3) characterized by central corneal ulcers, stromal thinning, and melting requiring urgent care.
Potential vision loss if NK is not detected and managed early.